Detalhe da pesquisa
1.
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
Ann Oncol
; 35(4): 364-380, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244928
2.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Ann Oncol
; 34(2): 200-211, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423745
3.
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Leukemia
; 32(1): 102-110, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28584253